NCT01495520.

Trial name or title	NCT01495520
Methods	Study design: cross‐over trial Duration of follow‐up: 30 days Method of randomisation: not described Method of concealment of allocation: not described Blinding: double‐blind (Subject, Caregiver, Investigator) Power calculation: not mentioned Phases of the study: 1 (treatment phase)
Participants	Total number: 100 (estimated) Country of enrolment: Italy Setting/location: not specified Diagnostic criteria (stable angina pectoris): coronary artery disease (macrovascular angina) Comorbidities: none Inclusion criteria: Symptoms of palpitations Angiographically‐proven coronary artery disease Stable conditions No recent acute coronary syndromes Able to understand and willing to sign the informed consent form Symptomatic patients (palpitation) with stable angina pectoris already on therapy with beta‐blockers and/or calcium antagonists Exclusion criteria: Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours Severe renal failure Severe hepatic failure
Interventions	Number of intervention groups: 2 Concomitant medications: not described Excluded medications: not described Placebo group Intervention: placebo Duration of intervention: 30 days Ranolazine group Intervention: ranolazine (type of formulation not specified) 750 mg twice daily Duration of intervention: 30 days
Outcomes	Total number of outcomes: 2 (occurrence of symptoms of palpitations, occurrence of arrhythmia in case of symptoms of palpitations) OUTCOMES No outcome meets the inclusion criteria
Starting date	January 2014
Contact information	Francesco Pelliccia, MD +39064997 f.pelliccia@mclink.it
Notes	Source of funding: University of Roma La Sapienza